Company news

Evommune, Inc. news in 2026

Evommune, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress

October 1, 2026

Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress

September 23, 2026

Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Atopic Dermatitis

September 8, 2026

Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights

August 6, 2026

Evommune Initiates Phase 2b Clinical Trial of MRGPRX2 Inhibitor EVO756 in Migraine Prophylaxis

July 30, 2026

Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Chronic Spontaneous Urticaria

June 29, 2026

Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights

May 7, 2026

Evommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in Migraine

April 6, 2026

Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights

March 5, 2026

Evommune Announces $125 Million Private Placement

February 12, 2026

Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis

February 10, 2026

Decks in 2026